140 related articles for article (PubMed ID: 19149499)
1. Evaluation of human plasma protein binding of trabectedin (Yondelis, ET-743).
Beumer JH; Lopez-Lazaro L; Schellens JH; Beijnen JH; van Tellingen O
Curr Clin Pharmacol; 2009 Jan; 4(1):38-42. PubMed ID: 19149499
[TBL] [Abstract][Full Text] [Related]
2. In vitro studies on the metabolism of trabectedin (YONDELIS) in monkey and man, including human CYP reaction phenotyping.
Vermeir M; Hemeryck A; Cuyckens F; Francesch A; Bockx M; Van Houdt J; Steemans K; Mannens G; Avilés P; De Coster R
Biochem Pharmacol; 2009 May; 77(10):1642-54. PubMed ID: 19426702
[TBL] [Abstract][Full Text] [Related]
3. Trabectedin and its C subunit modified analogue PM01183 attenuate nucleotide excision repair and show activity toward platinum-resistant cells.
Soares DG; Machado MS; Rocca CJ; Poindessous V; Ouaret D; Sarasin A; Galmarini CM; Henriques JA; Escargueil AE; Larsen AK
Mol Cancer Ther; 2011 Aug; 10(8):1481-9. PubMed ID: 21622731
[TBL] [Abstract][Full Text] [Related]
4. The unique biological features of the marine product Yondelis (ET-743, trabectedin) are shared by its analog ET-637, which lacks the C ring.
Erba E; Cavallaro E; Damia G; Mantovani R; Di Silvio A; Di Francesco AM; Riccardi R; Cuevas C; Faircloth GT; D'Incalci M
Oncol Res; 2004; 14(11-12):579-87. PubMed ID: 15666999
[TBL] [Abstract][Full Text] [Related]
5. Ascites interferes with the activity of lurbinectedin and trabectedin: Potential role of their binding to alpha 1-acid glycoprotein.
Erba E; Romano M; Gobbi M; Zucchetti M; Ferrari M; Matteo C; Panini N; Colmegna B; Caratti G; Porcu L; Fruscio R; Perlangeli MV; Mezzanzanica D; Lorusso D; Raspagliesi F; D'Incalci M
Biochem Pharmacol; 2017 Nov; 144():52-62. PubMed ID: 28782526
[TBL] [Abstract][Full Text] [Related]
6. Metabolism of trabectedin (ET-743, Yondelis) in patients with advanced cancer.
Beumer JH; Rademaker-Lakhai JM; Rosing H; Hillebrand MJ; Bosch TM; Lopez-Lazaro L; Schellens JH; Beijnen JH
Cancer Chemother Pharmacol; 2007 May; 59(6):825-37. PubMed ID: 16988825
[TBL] [Abstract][Full Text] [Related]
7. Yondelis (trabectedin, ET-743): the development of an anticancer agent of marine origin.
van Kesteren Ch; de Vooght MM; López-Lázaro L; Mathôt RA; Schellens JH; Jimeno JM; Beijnen JH
Anticancer Drugs; 2003 Aug; 14(7):487-502. PubMed ID: 12960733
[TBL] [Abstract][Full Text] [Related]
8. Trabectedin (ET-743): evaluation of its use in advanced soft-tissue sarcoma.
Schöffski P; Wolter P; Clement P; Sciot R; De Wever I; Wozniak A; Stefan C; Dumez H
Future Oncol; 2007 Aug; 3(4):381-92. PubMed ID: 17661712
[TBL] [Abstract][Full Text] [Related]
9. Increased DNA binding specificity for antitumor ecteinascidin 743 through protein-DNA interactions?
García-Nieto R; Manzanares I; Cuevas C; Gago F
J Med Chem; 2000 Nov; 43(23):4367-9. PubMed ID: 11087561
[No Abstract] [Full Text] [Related]
10. Trabectedin: Ecteinascidin 743, Ecteinascidin-743, ET 743, ET-743, NSC 684766.
Drugs R D; 2006; 7(5):317-28. PubMed ID: 16922593
[TBL] [Abstract][Full Text] [Related]
11. Trabectedin (ET-743, Yondelis) is a substrate for P-glycoprotein, but only high expression of P-glycoprotein confers the multidrug resistance phenotype.
Beumer JH; Buckle T; Ouwehand M; Franke NE; Lopez-Lazaro L; Schellens JH; Beijnen JH; van Tellingen O
Invest New Drugs; 2007 Feb; 25(1):1-7. PubMed ID: 16633714
[TBL] [Abstract][Full Text] [Related]
12. Disposition and toxicity of trabectedin (ET-743) in wild-type and mdr1 gene (P-gp) knock-out mice.
Beumer JH; Franke NE; Tolboom R; Buckle T; Rosing H; Lopez-Lazaro L; Schellens JH; Beijnen JH; van Tellingen O
Invest New Drugs; 2010 Apr; 28(2):145-55. PubMed ID: 19238326
[TBL] [Abstract][Full Text] [Related]
13. Trabectedin (Yondelis, formerly ET-743), a mass balance study in patients with advanced cancer.
Beumer JH; Rademaker-Lakhai JM; Rosing H; Lopez-Lazaro L; Beijnen JH; Schellens JH
Invest New Drugs; 2005 Oct; 23(5):429-36. PubMed ID: 16133794
[TBL] [Abstract][Full Text] [Related]
14. In-vitro cytotoxicity of ET-743 (Trabectedin, Yondelis), a marine anti-cancer drug, in the Hep G2 cell line: influence of cytochrome P450 and phase II inhibition, and cytochrome P450 induction.
Brandon EF; Meijerman I; Klijn JS; den Arend D; Sparidans RW; Lázaro LL; Beijnen JH; Schellens JH
Anticancer Drugs; 2005 Oct; 16(9):935-43. PubMed ID: 16162970
[TBL] [Abstract][Full Text] [Related]
15. HPLC-MS/MS method to measure trabectedin in tumors: preliminary PK study in a mesothelioma xenograft model.
Ceriani L; Ferrari M; Zangarini M; Licandro SA; Bello E; Frapolli R; Falcetta F; D'Incalci M; Libener R; Grosso F; Aviles P; Zucchetti M
Bioanalysis; 2015; 7(15):1831-42. PubMed ID: 26295985
[TBL] [Abstract][Full Text] [Related]
16. The inefficiency of incisions of ecteinascidin 743-DNA adducts by the UvrABC nuclease and the unique structural feature of the DNA adducts can be used to explain the repair-dependent toxicities of this antitumor agent.
Zewail-Foote M; Li VS; Kohn H; Bearss D; Guzman M; Hurley LH
Chem Biol; 2001 Nov; 8(11):1033-49. PubMed ID: 11731295
[TBL] [Abstract][Full Text] [Related]
17. Development of Yondelis (trabectedin, ET-743). A semisynthetic process solves the supply problem.
Cuevas C; Francesch A
Nat Prod Rep; 2009 Mar; 26(3):322-37. PubMed ID: 19240944
[TBL] [Abstract][Full Text] [Related]
18. Trabectedin: ET 743, ecteinascidin 743, Yondelis.
Drugs R D; 2003; 4(1):75-81. PubMed ID: 12568645
[No Abstract] [Full Text] [Related]
19. A review of trabectedin (ET-743): a unique mechanism of action.
D'Incalci M; Galmarini CM
Mol Cancer Ther; 2010 Aug; 9(8):2157-63. PubMed ID: 20647340
[TBL] [Abstract][Full Text] [Related]
20. Trabectedin in soft tissue sarcomas.
Brodowicz T
Future Oncol; 2014 Jun; 10(8 Suppl):s1-5. PubMed ID: 25048043
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
